It is not news that cannabis-based medicines have been used for millennia around the world in the treatment of conditions and diseases such as chronic pain; epilepsy; neuropsychiatric disorders; nausea and vomiting related to chemotherapy; symptoms associated with autistic spectrum disorder; amyotrophic lateral sclerosis; rheumatoid arthritis, among others. However, this topic has been the subject of recent discussions due to the progressive dissemination of scientific data proving the efficacy and safety of their uses. New scientific research and clinical studies are expected, not to mention the revision/alteration of legislation in some countries so that the cultivation, production, commercialization and use of cannabis-based medicines becomes more viable and comprehensive.
Recent Posts
- Press Play on American IP: AI Can’t Scratch the Soundtrack to World IP Day
- Other Barks & Bites for Friday, April 25: World IP Day 2025 Celebrates Musicians; Texas A&M to Lead Center for Advanced Aviation Technologies; and Tenth Circuit Affirms Specialty Metals Trade Secret Dismissal
- Judges Seem Frustrated with Judicial Council Arguments in Newman v. Moore Case
- Federal Circuit Reverses PTAB Win for Apple, Finding Board Erred in Its Applicant-Admitted Prior Art Analysis
- IPWatchdog Masters Panelists Urge U.S. Government to Get Organized When It Comes to AI